Serum MCP-1 Levels in Pancreatic Cancer and Obesity
Author Information
Author(s): Jennifer Sullivan, Qiaoke Gong, Terry Hyslop, Harish Lavu, Galina Chipitsyna, Charles J. Yeo, Hwyda A. Arafat
Primary Institution: Thomas Jefferson University
Hypothesis
Serum MCP-1 levels are elevated in obese PDA patients.
Conclusion
MCP-1 is a promising biomarker in pancreatic cancer that may help distinguish between PDA and IPMN patients.
Supporting Evidence
- Log MCP-1 values were significantly elevated in patients with BMI ≥ 37.5.
- In patients with BMI < 37.5, average log MCP-1 values were significantly elevated in PDA patients compared to IPMN patients.
- Higher log MCP-1 levels correlated with increased age within the IPMN group.
- Patients in the highest quartile of log MCP-1 were 6.2 times more likely to have pancreatic cancer.
Takeaway
This study found that a substance called MCP-1 in the blood is higher in obese patients with pancreatic cancer, which might help doctors tell the difference between cancer and non-cancer cases.
Methodology
ELISA was used to analyze MCP-1 serum levels in patients with PDA and IPMN, and statistical analyses were performed to assess relationships with clinical parameters.
Potential Biases
The study may have biases due to its retrospective nature and the specific patient population studied.
Limitations
The study was limited to a small sample size and focused only on surgically resected patients, which may not represent the broader population.
Participant Demographics
The average age of PDA patients was 64.7 years, with a mean BMI of 26.6 kg/m2.
Statistical Information
P-Value
0.04
Confidence Interval
[1.1, 37.4]
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website